● Recruiting

Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)

Condition: Potentially Resectable Hepatocellular Carcinoma · Sponsor: Shanghai Zhongshan Hospital

PhasePhase 2/Phase 3

Planned participants398

Who can joinAll sexes, 18 Years to 75 Years

Healthy volunteersNo

About this study

The purpose of this phase 2/3 study is to investigate the efficacy and safety of camrelizumab combined with rivoceranib and hepatic arterial infusion chemotherapy (HAIC) as conversion therapy for Potentially Resectable HCC.

This description comes directly from the study's public registry record.

Talk to the study team

Huichuan Sun, MD, PHD · sun.huichuan@zs-hospital.sh.cn · sun.huichuan@zs-hospital.sh.cn

Always discuss trial participation with your own doctor first.

Locations (2)

Harbin Medical University Cancer Hospital	Harbin, Heilongjiang, China	Recruiting
Zhongshan Hospital	Shanghai, Shanghai Municipality, China	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06796803